Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phenylalanine Amide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.70 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 2/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.70 |
| ▸ | ALPI | P09923 | 1/20 | 0.70 |
| ▸ | PKM | P14618 | 1/20 | 0.70 |
| ▸ | XIAP | P98170 | 1/20 | 0.70 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.58 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.55 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.55 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.52 |
| ▸ | LAP3 | P28838 | 3/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | CTSC | P53634 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylalanine Amide SCHEMBL353593 | 1.00 | SLC7A5 (0.70) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine Amide SCHEMBL354542 | 1.00 | SLC7A5 (0.70) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine Amide SCHEMBL23002157 | 1.00 | SLC7A5 (0.70) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine Amide SCHEMBL244303 | 0.98 | SLC7A5 (0.73) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine Amide SCHEMBL244302 | 0.98 | SLC7A5 (0.73) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine Amide SCHEMBL353251 | 0.98 | SLC7A5 (0.73) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine Amide SCHEMBL11349868 | 0.98 | SLC7A5 (0.73) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine Amide SCHEMBL7613303 | 0.96 | SLC7A5 (0.70) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine Amide SCHEMBL11569548 | 0.96 | SLC7A5 (0.70) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine Amide SCHEMBL28278266 | 0.96 | SLC7A5 (0.70) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0081838-B1 | CYCLOHEXYL AND PHENYL SUBSTITUTED ENKEPHALINS | G.D. Searle & Co. (US) | 1988-04-27 | — | — | EP | claimed |
| US-20250002531-A1 | PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-01-02 | — | — | US | disclosed |
| US-12037414-B2 | Processes for preparing pharmaceutically relevant peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11484525-B2 | Mu opioid receptor modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-11-01 | — | — | US | disclosed |
| EP-3319444-B1 | MU OPIOID RECEPTOR MODULATORS | UNIV CALIFORNIA (US) | 2022-03-09 | — | — | EP | disclosed |
| CN-113831392-A | Method for producing drug-related peptides | 康德生物医疗技术公司 | 2021-12-24 | — | — | CN | disclosed |
| CN-107530395-B | Method for producing drug-related peptides | 康德生物医疗技术公司 | 2021-10-22 | — | — | CN | disclosed |
| WO-2021087082-A1 | PRODRUGS OF ITACONATE AND METHYL ITACONATE | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-05-06 | — | — | WO | disclosed |
| EP-3800192-A1 | PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES | Stealth Biotherapeutics Corp (MC) | 2021-04-07 | — | — | EP | disclosed |
| US-10954251-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-03-23 | — | — | US | disclosed |
| EP-0674652-A1 | DOLOSTATIN ANALOG | BASF AKTIENGESELLSCHAFT (DE) | 1995-10-04 | — | — | EP | disclosed |
| CN-1095724-A | New peptides, its preparation and application | BASF AG (DE) | 1994-11-30 | — | — | CN | disclosed |
| WO-1994013695-A1 | DOLOSTATIN ANALOG | BASF AKTIENGESELLSCHAFT (DE) | 1994-06-23 | — | — | WO | disclosed |
| EP-0598753-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1994-06-01 | — | — | EP | disclosed |
| WO-1993002090-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1993-02-04 | — | — | WO | disclosed |
| EP-0524161-A1 | Manganese complexes of nitrogen containing macrocyclic ligands effective as catalysts for dismutating superoxide | MONSANTO COMPANY (US) | 1993-01-20 | — | — | EP | disclosed |
| EP-0317959-A2 | Anti-ulcer composition | Okamoto, Shosuke (JP) | 1989-05-31 | — | — | EP | disclosed |
| US-4761495-A | Method relating to preparation of aspartyl peptides | ISOCHEM S.A. (FR) | 1988-08-02 | — | — | US | disclosed |
| EP-0081838-B1 | CYCLOHEXYL AND PHENYL SUBSTITUTED ENKEPHALINS | G.D. Searle & Co. (US) | 1988-04-27 | — | — | EP | disclosed |
| US-4366250-A | Preparation process of optically active α-aminated acids by biological hydrolysis of nitriles | ANVAR (FR) | 1982-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002531-A1 | PROCESSES FOR PREPARING PHARMACEUTICALLY RELEVANT PEPTIDES | ADM2, VIP, PEPD | PTGS1 4677/4885HDAC8 4728/4885SLC7A5 402/4885 |
| US-11484525-B2 | Mu opioid receptor modulators | OPRM1, OPRK1, OPRD1 | PTGS1 630/4885HDAC8 2097/4885SLC7A5 2755/4885 |
| US-10954251-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | PRKX, PRKCQ, PRKACA | PTGS1 1459/4885HDAC8 2806/4885SLC7A5 2580/4885 |
| US-12037414-B2 | Processes for preparing pharmaceutically relevant peptides | ADM2, VIP, PEPD | PTGS1 4677/4885HDAC8 4728/4885SLC7A5 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.